Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of diabetes and its complications"
DOI: 10.1016/j.jdiacomp.2017.01.012
Abstract: AIMS Experimental and animal studies have supported the hypothesis that dipeptidyl peptidase-4 inhibitors (DPP-4i) may accelerate tumor metastasis. The aim was to analyze the relationships between DPP-4i therapy with risk of metastases in type 2… read more here.
Keywords: digestive organ; breast prostate; risk metastases; type diabetes ... See more keywords